Startups
MOMM develops high-sensitivity rapid diagnostic tests. Our technology combines the commercial advantage of lateral flow immunoassays, with the sensitivity of ELISA, and reader simplicity similar to blood glucose meters - opening previously laboratory-based markets for office- and self-testing.
Our first test in development is a rapid test for preeclampsia, offering unprecedented sensitivity at the point-of-care. Preeclampsia is a significant health problem and costs burden (1/3 of obstetric costs; over 2B USD in the US alone). It affects 3-8% of all pregnancies and may lead to severe short- and long-term complications. Immediate information during pregnancy check-ups helps doctors to optimize treatment, reduce stress and anxiety for expectant mothers, save lives and reduce costs.
Our first test in development is a rapid test for preeclampsia, offering unprecedented sensitivity at the point-of-care. Preeclampsia is a significant health problem and costs burden (1/3 of obstetric costs; over 2B USD in the US alone). It affects 3-8% of all pregnancies and may lead to severe short- and long-term complications. Immediate information during pregnancy check-ups helps doctors to optimize treatment, reduce stress and anxiety for expectant mothers, save lives and reduce costs.
Overview
Location
Germany
Total raised
$500K
Investors 2
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
| VentureLab | venturelab.swiss |
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 12
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Nov 18, 2025 | University projects receive up to CHF 150K in First Ventures program | First Ventures is an initiative of the Gebert Rüf Stiftung designed to support bachelor’s and master’s students from Swiss Universities of Applied Sciences (UAS) in transforming their ideas into market-ready businesses. Projects receive up... |
| Aug 25, 2025 | Healthtech startups in the global spotlight | Eight companies have been selected to participate in the American Heart Association Heart and Brain Health Accelerator, the program dedicated to driving innovations that have the potential to enhance patient outcomes, lower costs and reduc... |
| Jul 21, 2025 | Seven startups selected for the Swiss-Israel Lean Launchpad | The Swiss-Israeli Lean Launchpad, powered by Innosuisse and managed by Swissnex as part of the Start-up Campsis a hybrid startup exchange program designed to give Swiss startups tailored access to Israel's vibrant startup ecosystem. The in... |
| Jun 16, 2025 | Access to global accelerators for three MedTech start-ups | MedTech Innovator (MTI), a global accelerator for medical technology start-ups, has announced the 65 companies selected for its 2025 Accelerator Cohort. One of these companies, representing the top four percent of nearly 1,500 global appli... |
| Dec 1, 2023 | Four startups to explore South Africa’s health challenges | |
| Nov 13, 2023 | Strong Swiss delegation at Medica Startup Park | |
| May 3, 2023 | New bearers of the Innosuisse Certificate ready for the next level | |
| Apr 1, 2022 | Venture Leaders Medtech 2022: 10 innovative startups will advance their global growth in Boston | |
| Apr 23, 2021 | Tech4Eva draws global interest |
Show more
Reviews 0
FAQ about MOMM Diagnostics GmbH
How much funding has MOMM Diagnostics GmbH raised?
MOMM Diagnostics GmbH has raised $500K in total across 1 funding round.
Who has invested in MOMM Diagnostics GmbH?
Parsers VC lists 2 investors of MOMM Diagnostics GmbH, among them VentureLab.
What has the press written about MOMM Diagnostics GmbH?
Parsers VC has collected 12 articles mentioning MOMM Diagnostics GmbH, among them “University projects receive up to CHF 150K in First Ventures program” (Nov 18, 2025) and “Healthtech startups in the global spotlight” (Aug 25, 2025).
Is MOMM Diagnostics GmbH still active?
Yes, MOMM Diagnostics GmbH is active; its latest activity on Parsers VC dates from Jan 12, 2026.